DRSYSTEMSTECH LTD.
DrSystems Tech Ltd is a clinical intelligence platform focused on AI-assisted robotic fusion biopsy, founded by interventional radiology specialist Prof.
Profile
AI-assisted robotic systems for precise prostate cancer biopsies.
DrSystems Tech Ltd is a clinical intelligence platform focused on AI-assisted robotic fusion biopsy, founded by interventional radiology specialist Prof. Dr. Aykut Recep Aktaş and commercial strategist Idris Khan.
The company emerged from clinical practice, with its technology validated through a 48-patient prospective study demonstrating a 47.9% cancer detection rate and 91.7% detection in high-risk PI-RADS 5 lesions. Its minimally invasive robotic system, protected by patents in the UK, Türkiye, and Qatar, targets prostate cancer diagnosis with precision exceeding traditional methods. The platform is backed by Turkish government funding via KOSGEB, the SME development agency, and has completed 50 clinical cases as of 2026.
DrSystems Tech positions itself as a clinical-first AI/ML platform, distinct from tech companies seeking medical applications. Its leadership combines deep clinical expertise with cross-border commercial strategy, targeting expansion in the UK, Türkiye, and GCC regions. Recent moves include securing strategic investment for GCC deployment and submitting clinical results to the Journal of Vascular and Interventional Radiology. The company’s AI engine iteratively improves from procedural data, creating a compounding clinical asset.
Who buys this
- Hospitals and medical centers specializing in interventional radiology
- Oncology diagnostic service providers
- Research institutions conducting clinical trials
- Government health agencies in emerging markets
- Private urology and radiology clinics
Strengths and what to watch
Strengths
- Clinically validated results with 91.7% detection rate in high-risk lesions, published in peer-reviewed studies
- Patent-protected robotic biopsy technology across multiple jurisdictions
- Government-backed funding and ethical approval from Akdeniz University
Watch for
- Dependence on founder-led clinical expertise with limited public data on team depth
- Concentration risk in prostate cancer diagnostics without diversified applications
- Unclear revenue model or commercial deployment scale beyond pilot studies
Recent moves
Key Information
- Founded
- 1992
- Headquarters
- San Diego, CA. Read
Frequently Asked Questions
What does DrSystems Tech do?
DrSystems Tech develops AI-assisted robotic systems for precise prostate cancer biopsies. Their platform combines robotic fusion biopsy with machine learning, achieving a 47.9% overall cancer detection rate and 91.7% for high-risk lesions. The technology is patent-protected in multiple countries and clinically validated through peer-reviewed studies.
How accurate is DrSystems Tech's prostate cancer detection?
Clinical studies show DrSystems Tech's system detects prostate cancer in 47.9% of biopsies overall, with 91.7% accuracy for high-risk PI-RADS 5 lesions. These results come from a 48-patient prospective study, demonstrating superior precision compared to traditional biopsy methods.
What makes DrSystems Tech's robotic biopsy system different?
DrSystems Tech's system combines AI with robotic precision for minimally invasive prostate biopsies. Unlike general tech companies, it's clinically developed by interventional radiology experts. The platform learns from procedural data, improving over time. Patents protect its technology in the UK, Türkiye, and Qatar.
Where is DrSystems Tech available?
DrSystems Tech currently operates in the UK, Türkiye, and is expanding into GCC regions. The company has completed 50 clinical cases as of 2026 and secured strategic investment for GCC deployment. It targets hospitals, diagnostic centers, and research institutions specializing in interventional radiology.
Who founded DrSystems Tech and why?
DrSystems Tech was founded by interventional radiology specialist Prof. Dr. Aykut Recep Aktaş and commercial strategist Idris Khan. The company emerged from clinical practice needs, combining medical expertise with business strategy to improve prostate cancer diagnosis through AI-assisted robotics.
What hospitals use DrSystems Tech's biopsy system?
DrSystems Tech serves hospitals, medical centers, and clinics specializing in interventional radiology and oncology diagnostics. While specific institutions aren't named, their technology is used in 50 clinical cases across regions where they hold patents, including the UK and Türkiye, with GCC expansion underway.
Sources
- www.drsystems.tech — Clinical validation data, patent filings, leadership bios
- vimeo.com — Clinical case study demonstration